Britain and America have signed a major commercial pact that will ensure zero duties on UK drug products going into the American market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has committed to increase funding on pharmaceuticals through the public health system. This commitment guarantees that duties on these crucial exports will be held at zero for a duration of three years.
This agreement follows previous warnings to hike import taxes on patented pharmaceutical imports, with figures floated up to one hundred percent.
"This arrangement with the United Kingdom bolsters the international landscape for innovative medicines and brings much-needed balance to American-British medicine commerce," an announcement noted.
Economic Impact
Drugs are one of the Britain's biggest exports to the US, which is by far the primary destination for large British pharmaceutical firms.
Export figures reveal that in the one-year period to the end of last September, the UK exported pharmaceutical products worth over eleven billion pounds to the US. This amount represented 17.4% of total UK exports in that timeframe.
"This agreement protects work, boosts investment and facilitates the UK to establish itself as a international leader for biotech and pharma," the Business and Trade Secretary remarked.
Specific British Pledges
The agreement entails several notable changes from the British government:
- Revised Affordability Limit: The UK will raise the price threshold at which it judges new medicines to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a goal to double overall health service expenditure on treatments from 0.3% of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The amount drug companies must return to the NHS to stay within budget will be limited at fifteen percent. In the past, refunds topped twenty percent.
Industry Background
This agreement follows a ongoing row between the drug companies and the ministers over medicine costs and approval rates.
The disagreement were heightened by claims that US consumers were paying several times more for the same drugs than people in the UK and Europe.
Recently, several significant pharmaceutical investments in the UK have been halted or abandoned, while multi-billion-dollar expansions have been pledged toward projects in the United States.
A senior figure publicly accepted that the NHS had to spend more on medicines, noting that its budget allocation on drugs had decreased as a proportion of its resources over the last ten years.
